Wedbush Downgrades TScan Therapeutics to Neutral, Lowers Price Target to $1

Benzinga Newsdesk www.benzinga.com Negative 90.2%

Neg 90.2% Neu 0% Pos 0%

Wedbush analyst David Nierengarten downgrades TScan Therapeutics (NASDAQ:TCRX) from Outperform to Neutral and lowers the price target from $5 to $1.